Sponsors (10)
The bill aims to speed, standardize, and make more transparent FDA pathways for OTC sunscreen ingredients and to promote prevention and non‑animal testing—potentially lowering skin cancer burden and improving product options—while raising risks of lower evidentiary standards, higher compliance costs, regulatory strain, and possible erosion of public trust.
Children, young adults, seniors and the general public: a stronger emphasis on sun‑safe behaviors and sunscreen use that should reduce skin cancer incidence and related morbidity.
Consumers and manufacturers: clearer and faster authorization pathways and consistent evidentiary standards for OTC sunscreen active ingredients, increasing product options and consumer confidence.
Taxpayers and patients: strengthens the prevention rationale that could reduce expensive skin cancer treatments and associated public and private health care costs over time.
Consumers (including children and other vulnerable groups): allowing more reliance on real‑world evidence, observational studies, and historical safety data risks lowering evidentiary standards so that some sunscreen actives reach market with less rigorous proof of safety or effectiveness.
Consumers and manufacturers: increased oversight pressure and deadlines (reports, expedited pathways) may prompt rushed implementation or approvals, creating regulatory uncertainty and potential safety or liability issues.
Small businesses, manufacturers and consumers: new regulatory standards, guidance development, and compliance obligations could raise development and compliance costs that are potentially passed on to consumers or inhibit smaller firms.
Based on analysis of 5 sections of legislative text.
Introduced June 3, 2025 by John Joyce · Last progress June 3, 2025
Requires the Department of Health and Human Services (via FDA) to create science-based standards for evaluating sunscreen active ingredients that explicitly allow real-world evidence, observational studies, and validated nonclinical (non-animal) test methods. It directs the FDA to incorporate those standards into its final administrative order for pending over-the-counter sunscreen active ingredient submissions and to issue guidance within 180 days on how sponsors may use non-animal alternatives. The bill also requires annual congressional reports on implementation and FDA progress, with those reports posted online.